BC-DXI-843
BC-DXI-843 is a potent and specific AIMP2-DX2 inhibitor with an IC50 of 0.92 μM, more than 100-fold selectivity over AIMP2 (IC50 >100 μM) in a luciferase assay. BC-DXI-843 acts as a promising lead targeting AIMP2-DX2 in lung cancer[1].
Product Specifications
CAS Number
2421117-98-6
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
Aminoacyl-tRNA Synthetase
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bc-dxi-843.html
Concentration
10mM
Purity
99.76
Solubility
DMSO : 250 mg/mL (ultrasonic)
Smiles
COC(C=C1)=CC=C1C2=CSC(NC([C@@H](NS(C3=CC=C(C)C=C3)(=O)=O)CC4=CNC5=C4C=CC=C5)=O)=N2
Molecular Formula
C28H26N4O4S2
Molecular Weight
546.66
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
PLAP (Placental Alkaline Phosphatase) (ALP/870), Biotin conjugate, 0.1mg/mL
